Today's Low
₹ 83.25
Today's High
₹ 86.80
52 Weeks Low
₹ 77.05
52 Weeks High
₹ 132.75
Lower
₹ 82.20
Upper
₹ 90.80
Bafna Pharmaceuticals Limited manufactures and sells generic pharmaceutical products and finished pharmaceutical formulations in India. It also exports its products. The company was founded in 1981 and is based in Chennai, India.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 36.1 | 48.5 | 48.7 | 77.2 | 122.3 | 127.1 | 156.5 | 178.6 | 136.6 |
Total Non-Current Assets | 35.2 | 71.0 | 89.6 | 101.1 | 69.5 | 72.7 | 71.9 | 74.5 | 77.2 |
Total Assets | 71.3 | 119.5 | 138.4 | 178.3 | 192.5 | 199.8 | 235.8 | 260.6 | 218.9 |
Total Current Liabilities | 17.1 | 70.8 | 59.9 | 81.5 | 95.1 | 111.1 | 135.4 | 160.0 | 121.8 |
Total Non-Current Liabilities | 3.0 | 29.8 | 41.3 | 54.7 | 39.9 | 16.0 | 30.7 | 32.3 | 32.6 |
Shareholder's Funds | 51.1 | 19.1 | 37.9 | 42.7 | 57.8 | 71.8 | 68.9 | 67.5 | 63.8 |
Total Liabilities | 71.3 | 119.5 | 138.4 | 178.3 | 192.5 | 199.8 | 235.8 | 260.6 | 218.9 |
The Industry Current Ratio stands at 2.21, vs the Current Ratio of 0.95, which results in a Negative aspect.
The Industry Quick Ratio stands at 1.54, vs the Quick Ratio of 0.74, which results in a Negative aspect.
The Industry Debt to Equity Ratio stands at 0.44, vs the Debt to Equity Ratio of 2.13, which results in a Negative aspect.
The Industry Price to BV stands at 6.09, vs the Price to BV of 0.00, which results in a Negative aspect.
Particulars | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|
Total Income | 42.5 | 43.6 | 47.2 | 65.0 | 85.3 | 138.8 | 185.3 | 175.8 | 128.6 |
Total Expenditure | 41.3 | 56.7 | 82.3 | 70.8 | 84.8 | 115.3 | 162.5 | 153.3 | 110.0 |
Operating Profit(Excl OI) | 1.5 | -12.7 | -3.8 | -4.7 | 2.5 | 28.4 | 24.7 | 25.5 | 20.1 |
Add: Other Income | 0.3 | 0.4 | 31.3 | 1.1 | 2.0 | 4.9 | 1.9 | 3.0 | 1.5 |
Operating Profit | 1.5 | -12.7 | -3.8 | -4.7 | 2.5 | 28.4 | 24.7 | 25.5 | 20.1 |
Less: Interest | 0.1 | 2.1 | 6.9 | 11.5 | 13.0 | 13.5 | 13.2 | 11.9 | 8.3 |
PBDT | 1.4 | -14.8 | -10.7 | -16.1 | -10.5 | 14.9 | 11.5 | 13.6 | 11.8 |
Less: Depreciation Amortization | 3.3 | 3.5 | 4.0 | 4.2 | 4.9 | 6.0 | 9.0 | 8.3 | 6.3 |
PBT & Exceptional Items | -1.9 | -18.3 | -14.7 | -20.4 | -15.3 | 8.9 | 2.5 | 5.4 | 5.5 |
Less: Exceptional Income Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.8 | 0.0 | 0.1 | -0.1 |
Profit Before Tax | -1.9 | -18.3 | -14.7 | -20.4 | -15.3 | 6.1 | 2.5 | 5.5 | 5.4 |
Less: Taxation | 0.0 | 1.1 | 2.2 | -0.9 | -0.2 | -0.2 | 1.1 | 1.5 | 3.5 |
Profit After Tax | -1.9 | -19.4 | -16.9 | -19.5 | -15.1 | 6.2 | 1.4 | 4.0 | 1.9 |
Earnings Per Share | -0.1 | -0.1 | -0.1 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The Industry PAT Growth stands at 16.78, vs the PAT Growth of -28.52, which results in a Negative aspect.
The Industry PAT Margin stands at 10.97, vs the PAT Margin of -29.34, which results in a Negative aspect.
The Industry Dividend Yield stands at 0.61, vs the Dividend Yield of 0.00, which results in a Negative aspect.
The Industry PE Ratio stands at 42.89, vs the PE Ratio of 0.00, which results in a Negative aspect.
Particulars | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | -1.9 | -18.3 | -14.7 | -20.4 | -15.3 | 6.2 | 2.5 | 5.5 | 5.4 |
Tax Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.3 | -0.5 | -0.9 | -1.1 |
Adjustment | -19.5 | 5.4 | -19.5 | 15.5 | 15.8 | -26.6 | 20.4 | 17.1 | 10.2 |
Changes In Working Capital | -1.9 | -18.3 | -14.7 | -20.4 | -15.3 | 6.2 | 2.5 | 5.5 | 5.4 |
Cash Flow after changes in Working Capital | -34.3 | -1.8 | -7.0 | -0.9 | 0.9 | 12.9 | 2.1 | 37.5 | 30.3 |
Cash Flow from Operating Activities | -34.3 | -1.8 | -7.0 | -0.9 | 0.9 | 10.7 | 1.6 | 36.6 | 29.2 |
Cash Flow from Investing Activities | 32.8 | 15.4 | 38.0 | -5.4 | -0.4 | 60.1 | -6.7 | -6.1 | -38.0 |
Cash Flow from Financing Activities | 7.3 | -13.8 | -30.6 | 6.3 | -0.6 | -70.8 | -13.2 | -11.9 | -0.7 |
Net Cash Inflow / Outflow | 5.8 | -0.2 | 0.3 | -0.1 | -0.1 | 0.0 | -18.3 | 18.6 | -9.5 |
Opening Cash & Cash Equivalents | 2.7 | 3.0 | 2.7 | 2.7 | 2.8 | 2.8 | 21.1 | 2.5 | 11.9 |
Closing Cash & Cash Equivalent | 8.5 | 2.7 | 3.0 | 2.7 | 2.7 | 2.8 | 2.8 | 21.1 | 2.5 |
The Industry PFCF Ratio stands at -64.89, vs the PFCF Ratio of -4.83, which results in a Positive aspect.
The Industry PCF RATIO stands at 19.98, vs the PCF RATIO of -58.20, which results in a Negative aspect.
Particulars | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 |
---|---|---|---|---|
Net Sales | 131.3 | 109.3 | 115.7 | 68.5 |
Total Income | 124.6 | 109.6 | 121.6 | 71.5 |
Total Expenditure | 88.9 | 107.0 | 119.4 | 97.2 |
PBIDT (Excl OI) | 42.5 | 2.2 | -3.8 | -28.7 |
Other Income | -6.7 | 0.3 | 5.9 | 3.0 |
Operating Profit | 35.7 | 2.5 | 2.2 | -25.7 |
Interest | 0.3 | -1.0 | 0.5 | 1.3 |
Exceptional Items | -8.4 | -217.2 | 0.0 | 0.0 |
PBDT | 27.1 | -213.6 | 1.7 | -26.9 |
Depreciation | 5.3 | 10.0 | 7.2 | 10.2 |
Profit Before Tax | 21.8 | -223.6 | -5.5 | -37.1 |
Tax | 15.8 | -0.4 | 0.4 | -15.8 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | 6.1 | -223.3 | -5.9 | -21.3 |
Net Profit | 6.1 | -223.3 | -5.9 | -21.3 |
ADDITIONAL INFOS: | ||||
Equity Capital | 23.7 | 236.6 | 236.6 | 236.6 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | 0.2 | -94.4 | -0.3 | -1.3 |
Operating Profit Margin | 27.2 | 2.3 | 1.9 | -37.5 |
Net Profit Margin | 4.6 | -204.4 | -5.1 | -31.1 |
The Industry Net Sales Growth stands at 7.82, vs the Net Sales Growth of -23.86, which results in a Negative aspect.
The Industry Mcap Growth stands at 0.22, vs the Mcap Growth of -1.17, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 90.50 | 91.96 | 87.82 |
R3 | 89.32 | 89.58 | 87.31 |
R2 | 88.13 | 88.26 | 87.14 |
R1 | 87.47 | 87.73 | 86.97 |
Pivot | 86.28 | 86.41 | 86.28 |
S1 | 85.62 | 85.88 | 86.63 |
S2 | 84.43 | 84.56 | 86.46 |
S3 | 83.77 | 84.03 | 86.29 |
S4 | 83.10 | 80.86 | 85.78 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
53.22
Neutral
RSI
43.43
Neutral
ROC
0.06
Bullish
UltimateOscillator
48.63
Neutral
Williams Indicator
-50.00
Neutral
CCI Indicator
-4.07
Neutral
MACD
-2,861.06
Bearish
Stochastic Indicator
61.31
Neutral
ATR
3.59
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|
Date Of Conduct | Board Meeting Details |
---|---|
12-02-2024 | Quarterly Results |
09-11-2023 | Quarterly Results |
11-08-2023 | Quarterly Results |
26-06-2023 | Inter alia, to consider and approve the appointment of : 1. Mr. Vinayak Dinesh Dendukuri (DIN: 07601309) as Additional Director designated as Whole-time Director ? Operation. 2. Mr. Upendar Mekala Reddy (DIN: 08898174) as Additional Director designated as Non-Executive Non-independent Director; 3. Mr. Krishna Yeachuri (DIN: 00066898) as Additional Director designated as Non-Executive Independent Director, and any other business with the permission of the Chair. |
27-05-2023 | Audited Results (Revised) |
24-05-2023 | Audited Results |
07-04-2023 | Inter alia, to consider and approve the appointment of Company Secretary cum Compliance Officer and any other business with the permission of the Chair |
08-02-2023 | Quarterly Results |
11-11-2022 | Quarterly Results |
11-08-2022 | Quarterly Results |
26-05-2022 | Audited Results |
21-03-2022 | Inter alia, to consider resignation and appointment of Company Secretary (KMP) of the Company and any other business with the permission of chair. |
10-02-2022 | Quarterly Results |
12-11-2021 | Rights Issue & Quarterly Results Inter alia also consider the following business: 1. To consider and approve the proposal for various avenues for raising funds, including and in particular Rights Issue to meet capital requirements of the Company. |
16-09-2021 | Inter alia, to consider the proposal of availing working capital / term loan facility for expansion program and any other business with the permission of the Chair |
05-08-2021 | Quarterly Results |
25-06-2021 | Audited Results |